Press Releases

Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy

Press Release: Availability of the Q2 2024 Aide-mémoire

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

Media Update: Sanofi update on Zantac litigation

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations